Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Entera Bio Ltd.NASDAQ: ENTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $2.24M rose 99.8% year over year, ahead of the +45.6% change in trailing-twelve-month research & development. Sequentially, it rose 30.6% from the prior quarter. Over 3 fiscal years it compounded at +1.3% a year.
Context
- Research & development amounted to 14295.2% of revenue in FY2025, up 11809.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +99.8% holds above the trailing-twelve-month pace of +45.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6M USD
- Year-over-year change
- +33.5%
- 4-year CAGR
- -3.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6M | +33.5% |
| FY2024 | 2024-12-31 | 4.5M | +1.0% |
| FY2023 | 2023-12-31 | 4.45M | -23.0% |
| FY2022 | 2022-12-31 | 5.78M | -14.6% |
| FY2021 | 2021-12-31 | 6.77M | — |
Research & Development vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's LTM Mar 2026 research & development of $7.12M is the 9th highest of the 10 companies compared; the peer median is $37.82M.
- Its year-over-year change of +45.6% is the 2nd highest of 10, against a peer median of -27.2%.
- Over three fiscal years its annual growth of +1.3% compares with a peer median of -6.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $96.1M | -9.9% | +48.0% | — | |
| LTM Mar 2026 | $51.51M | -27.2% | -33.9% | — | |
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
| LTM Mar 2026 | $38.53M | -58.1% | — | 31.1% | |
| LTM Mar 2026 | $37.82M | -33.6% | -23.5% | 3297.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M | +11.2% | +29.0% | 279.0% |
| LTM Mar 2026 | $27.77M | -70.1% | -6.9% | 50.7% | |
| LTM Mar 2026 | $21.18M | +82.5% | +30.2% | — | |
| LTM Mar 2026 | $7.12M | +45.6% | +1.3% | — | |
| LTM Apr 2026 | $4.56M | -27.4% | -8.9% | — | |
| Peer median (excluding ENTX) | $37.82M | -27.2% | -6.5% | 274.8% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 571K | 134K | 0 | 181K | 42K |
| Cost of Revenue | 373K | 165K | 56K | 172K | 42K |
| Gross Profit | 198K | (31K) | (56K) | 9K | 0 |
| Gross Margin | 34.7% | -23.1% | — | 5.0% | 0.0% |
| Research & Development | 6.77M | 5.78M | 4.45M | 4.5M | 6M |
| Selling, General & Admin | 5.69M | 7.25M | 4.43M | 5.1M | 5.53M |
| Operating Expenses | 12.42M | 13.04M | 8.88M | 9.59M | 11.53M |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| EBITDA | (12.16M) | (12.87M) | (8.8M) | (9.48M) | (11.41M) |
| EBITDA Margin | -2130.3% | -9604.5% | — | -5238.1% | -27164.3% |
| Operating Income | (12.22M) | (13.07M) | (8.94M) | (9.59M) | (11.53M) |
| Operating Margin | -2139.6% | -9752.2% | — | -5295.6% | -27450.0% |
| Interest Income | 0 | 83K | 31K | 58K | 0 |
| Interest Expense | 29K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (29K) | 134K | 80K | 58K | 90K |
| Income Before Tax | (12.25M) | (12.93M) | (8.86M) | (9.53M) | (11.44M) |
| Pre-Tax Margin | -2144.7% | -9652.2% | — | -5263.5% | -27235.7% |
| Income Tax Expense | (59K) | 137K | 29K | 14K | 0 |
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Net Margin | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
| EPS (Basic) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| EPS (Diluted) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| Weighted Avg Shares | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M |
| Weighted Avg Shares (Diluted) | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M |
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.